KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

Company Overview - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases [3] - The company utilizes a proprietary mesenchymal stem cell secretome (MSC-S) platform for its investigational therapies [3] Product Development - KALA's lead product candidate, KPI-012, is designed to address impaired corneal healing, specifically for persistent corneal epithelial defect (PCED) [3] - KPI-012 has received Orphan Drug and Fast Track designations from the U.S. FDA, indicating its potential significance in treating rare diseases [3] - The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision [3] - Preclinical studies are underway to evaluate the MSC-S platform's potential for treating retinal degenerative diseases, including Retinitis Pigmentosa and Stargardt Disease [3] Upcoming Events - KALA management will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 11:50 a.m. ET [1] - One-on-one meetings with management will also be available on the same day [1]